DexCom (DXCM) Peer Comparison
$82.97
$-1.79
(-2.11%)
As on 03-Nov-2026 16:28EST
Market cap
$30,690 Mln
Revenue (TTM)
$5,104 Mln
P/E Ratio
32.4
P/B Ratio
12.1
Div. Yield
0 %
Edit
| DexCom (DXCM) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
30,690 | 262,217 | 180,946 | 166,594 | 152,620 |
Revenue ($ Mln) |
5,104 | 47,351 | 48,229 | 25,608 | 11,578 |
Net Profit ($ Mln) |
991.00 | 7,083.00 | 4,701.00 | 4,331.00 | 2,957.20 |
Net Margin (%) |
19.41 | 14.96 | 9.75 | 16.91 | 25.54 |
RoE (%) |
36.09 | 13.25 | 18.06 | 8.13 | 17.58 |
Price to Earnings |
32.40 | 37.40 | 38.87 | 39.24 | 54.27 |
Price-To-Book |
12.11 | 4.75 | 3.48 | 3.07 | 9.92 |
Income Statement ($ Mln)
| DexCom (DXCM) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
5,104.40 | 47,351.00 | 48,229.00 | 25,608.00 | 11,578.00 |
|
Cost of Revenue
|
1,867.00 | 27,729.00 | 20,681.00 | 10,603.00 | 3,798.50 |
|
Gross Profit
|
2,801.90 | 18,239.00 | 24,607.00 | 14,970.00 | 6,642.30 |
|
Operating Expenses
|
2,013.60 | 11,106.00 | 20,197.00 | 9,787.00 | 4,495.40 |
|
Operating Profit (EBIT)
|
1,223.80 | 8,515.00 | 7,351.00 | 5,218.00 | 3,284.10 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
1,262.40 | 7,869.00 | 6,562.00 | 4,818.00 | 3,619.00 |
|
Provision for Tax
|
271.40 | 742.00 | 1,861.00 | 487.00 | 645.90 |
|
Profit after Tax (Net Income)
|
991.00 | 7,083.00 | 4,701.00 | 4,331.00 | 2,957.20 |
|
Minority Interest
|
0.00 | -16.00 | 0.00 | 0.00 | -15.90 |
|
Consolidated Profit
|
0.00 | 1,964.00 | 1,776.00 | 1,197.00 | 0.00 |
Liabilities ($ Mln)
| DexCom (DXCM) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
2,535.40 | 54,767.00 | 0.00 | 53,621.00 | 15,986.20 |
|
Minority Interest
|
0.00 | -16.00 | 0.00 | 0.00 | -15.90 |
|
Non-Current Liabilities
|
1,450.80 | 45,296.00 | 0.00 | 30,610.00 | 698.30 |
|
Current Liabilities
|
2,252.60 | 14,170.00 | 0.00 | 9,050.00 | 2,533.00 |
|
Total Liabilities
|
6,339.90 | 110,343.00 | 86,713.00 | 83,464.00 | 20,631.20 |
Assets ($ Mln)
| DexCom (DXCM) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
2,322.80 | 88,618.00 | 0.00 | 78,494.00 | 10,920.80 |
|
Current Assets
|
3,916.00 | 25,615.00 | 0.00 | 14,787.00 | 8,428.30 |
|
Total Assets
|
6,339.90 | 110,343.00 | 86,713.00 | 83,464.00 | 20,631.20 |
|
Total Debt*
|
1,392.90 | 41,370.00 | 0.00 | 26,482.00 | 0.00 |
|
Net Current Assets
|
1,663.40 | 0.00 | 0.00 | 5,737.00 | 5,895.30 |
Cashflow ($ Mln)
| DexCom (DXCM) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
1,440.70 | 7,818.00 | 9,566.00 | 6,416.00 | 3,030.50 |
|
Cash Flow from Investing Activities
|
536.00 | -4,047.00 | -2,422.00 | -1,196.00 | 665.80 |
|
Cash from Financing Activities
|
-1,686.40 | 1,801.00 | -6,309.00 | -2,961.00 | -2,364.10 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| DexCom (DXCM) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
18.95 | 7.69 | 10.03 | 5.25 | 16.46 |
|
ROE (%)
|
36.09 | 13.25 | 18.06 | 8.13 | 17.58 |
|
ROA (%)
|
10.25 | 5.50 | 9.52 | 4.59 | 13.74 |
|
EBIT Margin (%)
|
24.99 | 13.63 | 11.82 | 20.22 | 33.80 |
|
Net Margin (%)
|
19.41 | 14.96 | 9.75 | 16.91 | 25.54 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| DexCom (DXCM) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
13.03 | 8.27 | 10.00 | 5.52 | 20.45 |
|
EBIT Growth (%)
|
30.45 | -24.37 | -34.24 | 16.46 | 23.61 |
|
Net Profit Growth (%)
|
37.51 | 7.81 | -66.37 | 23.64 | 7.66 |
|
EPS Growth (%)
|
43.04 | 9.68 | -66.31 | 26.16 | 9.30 |
|
Book Value Growth (%)
|
-1.20 | 9.37 | -- | 6.02 | -2.83 |
Valuation Ratios
| DexCom (DXCM) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
31.66 | 32.43 | 33.55 | 45.04 | 71.47 |
|
Price / Book Value
|
9.64 | 4.09 | 4.20 | 3.10 | 11.45 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
19.04 | 21.61 | 18.87 | 25.42 | 49.76 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| DexCom (DXCM) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.49 | 0.00 | 0.29 | 0.45 | 0.00 |
|
Short term debt to equity ratio
|
0.01 | 0.04 | 0.06 | 0.04 | 0.00 |
|
Current Ratio
|
1.74 | 1.81 | 1.58 | 1.63 | 3.33 |
|
Quick Ratio
|
1.40 | 1.41 | 1.18 | 1.29 | 2.49 |
|
Interest Coverage
|
95.21 | 6.12 | 8.37 | 14.38 | -- |
Operating Efficiency Ratios
| DexCom (DXCM) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
23.24 | 20.33 | 0.00 | 20.02 | 14.87 |
|
Asset Turnover
|
0.53 | 0.37 | 0.98 | 0.27 | 0.54 |
|
Receivable days
|
91.02 | 82.76 | 61.20 | 61.72 | 54.16 |
|
Inventory Days
|
115.04 | 72.19 | 117.44 | 91.69 | 177.54 |
|
Payable days
|
67.71 | 46.50 | 78.11 | 68.44 | 23.93 |
|
Cash Conversion Cycle
|
138.35 | 108.45 | 100.53 | 84.97 | 207.78 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
